StevenMLarsonMDFACR

PubMed

• [F]TFB PET/CT misses intense [I]iodine-avid metastases after redifferentiation therapy in metastatic thyroid cancer.
  Philipp Backhaus, Keith S Pentlow, Alan L Ho, Audrey Mauguen, James A Fagin
  EJNMMI Research. 2024-10-08
• Theranostic GPA33-Pretargeted Radioimmunotherapy of Human Colorectal Carcinoma with a BivalentLu-Labeled Radiohapten.
  Brett A Vaughn, Sang-Gyu Lee, Daniela Burnes Vargas, Shin Seo, Sara S Rinne
  Journal of Nuclear Medicine. 2024-10-01
• 1 citations
  Patient metabolic profile defined by liver and muscleF-FDG PET avidity is independently associated with overall survival in gastric cancer.
  Gerardo A Vitiello, Vetri Sudar Jayaprakasam, Laura H Tang, Mark A Schattner, Yelena Y Janjigian
  Gastric Cancer. 2024-05-01

Journal Articles

• Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers  
  Steven M Larson, Sofia Haque, Duan Li, R Michael Tuttle, Mona M Sabra, Alan L Ho, Eric J Sherman, Ravinder K Grewal, James A Fagin, David G Pfister, Ronald A Ghossein, The Journal of Clinical Endocrinology and Metabolism
• Bone metastases in castration-resistant prostate cancer: expression on PET and overall survival  
  Vargas HA, Wassberg C, Fox JJ, Wibmer A, Goldman DA, Kuk D, Gonen M, Larson SM, Morris MJ, Scher HI, Hricak H, Radiology, 1/1/2014
• Phase II study of lutetium-177 labeled anti-prostate-specific membraneantigen (PSMA) monoclonal antibody J591 for metastatic castration-resistantprostate cancer  
  Tagawa ST, Milowsky MI, Morris MJ, Vallabhajosula S, Christos PJ, Akhtar NH, Goldsmith SJ, Osborne J, Larson SM, Pandit-Taskar N, Scher HI, Bander NH, Nanus DM, Clin Cancer Res, 1/28/2013
• Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer  
  Ho AL, Grewal RK, Leboeuf R, Sherman EJ, Pfister DG, Deandreis D, Pentlow KS, Zanzonico PB, Haque S, Gavane S, Ghossein RA, Ricarte-Filho JC, Domínguez JM, Shen R, Tut..., N Engl J Med, 1/1/2013
• Improving the chance of cure of follicular lymphoma by combining immunotherapy and radioimmunotherapy based on anti-CD20 antibodies?  
  Buchegger F, Mach JP, Press OW, Bischof Delaloye A, Larson SM, Prior JO, Ketterer N, Ann Oncol, 1/1/2013
• Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma  
  Stelter L, Evans MJ, Jungbluth AA, Longo VA, Zanzonico P, Ritter G, Bomalaski JS, Old L, Larson SM, Mol Imaging, 1/1/2013
• Radioimmunotherapy Combined with Maintenance Anti-CD20 Antibody May Trigger Long-Term Protective T Cell Immunity in Follicular Lymphoma Patients  
  Buchegger F, Larson SM, Mach JP, Chalandon Y, Dietrich PY, Cairoli A, Prior JO, Romero P, Daniel E, Speiser Clinical and Developmental Immunology, 1/1/2013
• A Novel Automated Platform for Quantifying the Extent of Skeletal Tumour Involvement in Prostate Cancer Patients Using the Bone Scan Index  
  Ulmert D, Kaboteh R, Fox JJ, Savage C, Evans MJ, Lilja H, Abrahamsson PA, Bjork T, Gerdtsson A, Bjartell A, Gjertsson P, Hoglund P, Lomsky M, Ohlsson M, Richter J, Sad..., Eur Urol, 1/27/2012
• Imaging androgen receptor signaling with a radiotracer tartgeting free prostate-specific antigen  
  Ulmert D, Evans MJ, Holland JP, Rice SL, Wongvipat J, Pettersson K, Abrahamsson PA, Scardino PT, Larson SM, Lilja H, Lewis JS, Sawyers CL, Cancer Discov, 1/1/2012
• Computer-aided quantitative bone scan assessment of prostate cancer treatment response  
  Brown MS, Chu GH, Kim HJ, Allen-Auerbach M, Poon C, Bridges J, Vidovic A, Ramakrishna B, Ho J, Morris MJ, Larson SM, Scher HI, Goldin JG, Nucl Med Commun, 1/1/2012
• Fluorine- labeled Dasatinib Nanoformulations as Targeted Molecular Imaging Probes in a PDGFB-driven Murine Glioblastoma Model  
  Benezra M, Hambardzumyan D, Penate-Medina O, Veach DR, Pillarsetty N, Smith-Jones P, Phillips E, Ozawa T, Zanzonico PB, Longo V, Holland EC, Larson SM, Bradbury MS, Neoplasia, 1/1/2012
• Bone scan index: a quantitative treatment response biomarker for castration- resistant metastatic prostate cancer  
  Dennis ER, Jia X, Mezheritskiy IS, Stephenson RD, Schoder H, Fox JJ, Heller G, Scher HI, Larson SM, Morris MJ, J Clin Oncol, 1/1/2012
• Molecular imaging of prostate  
  Fox JJ, Schoder H, Larson SM, Curr Opin Urol, 1/1/2012
• A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13R 2 tumor-restricted biomarker  
  Nguyen V, Conyers JM, Zhu D, Gibo DM, Hantgan RR, Larson SM, Debinski W, Mintz. A, Neuro Oncol, 1/1/2012
• High Dose Cytarabine and Mitoxantrone: An Effective Induction Regimen for High-Risk Acute Myeloid Leukemia (AML)  
  Larson SM, Campbell NP, Huo D, Artz A, Zhang Y, Gajria D, Green M, Weiner H, Daugherty C, Odenike O, Godley LA, Hyjek E, Gurbuxani S, Thirman M, Sipkins D, Van Besien ..., Leuk Lymphoma, 1/13/2011
• Five-Year Survival Is Similar in Thyroid Cancer Patients with Distant Metastases Prepared for Radioactive Iodine Therapy with either Thyroid Hormone Withdrawal or Reco...  
  Tala H, Robbins R, Fagin JA, Larson SM, Tuttle RM, J Clin Endocrinol Metab, 1/11/2011
• Evaluation of (18)F-FDG-PET for Early Detection of Suboptimal Response of Rectal Cancer to Preoperative Chemoradiotherapy: A Prospective Analysis  
  Leibold T, Akhurst TJ, Chessin DB, Yeung HW, Macapinlac H, Shia J, Minsky BD, Saltz LB, Riedel E, Mazumdar M, Paty PB, Weiser MR, Wong WD, Larson SM, Guillem JG, Surg Oncol, 1/8/2011
• 124I- huA33 Antibody Uptake Is Driven by A33 Antigen Concentration in Tissues from Colorectal Cancer Patients Imaged by Immuno-PET  
  O'Donoghue JA, Smith-Jones PM, Humm JL, Ruan S, Pryma DA, Jungbluth AA, Divgi CR, Carrasquillo JA, Pandit-Taskar N, Fong Y, Strong VE, Kemeny NE, Old LJ, Larson SM, J Nucl Med, 1/8/2011
• (124)I-huA33 antibody PET of colorectal cancer  
  Carrasquillo JA, Pandit-Taskar N, O'Donoghue JA, Humm JL, Zanzonico P, Smith-Jones PM, Divgi CR, Pryma DA, Ruan S, Kemeny NE, Fong Y, Wong D, Jaggi JS, Scheinberg DA, ..., J Nucl Med, 1/1/2011
• Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid  
  He P, Kramer K, Smith-Jones P, Zanzonico P, Humm J, Larson SM, Cheung NK, Eur J Nucl Med Mol Imaging, 1/1/2011
• Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid Erratum  
  He P, Kramer K, Smith-Jones P, Zanzonico P, Humm J, Larson SM, Cheung NK, Eur J Nucl Med Mol Imaging, 1/1/2011
• Erratum to: Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid  
  Smith-Jones P, Zanzonico P, Humm J, Larson SM, Cheung NK, Eur J Nucl Med Mol Imaging, 1/1/2011
• Optimizing tumor targeting of the lipophilic EGFR-binding radiotracer SKI 243 using a liposomal nanoparticle delivery system  
  Medina OP, Pillarsetty N, Glekas A, Punzalan B, Longo V, Gonen M, Zanzonico P, Smith-Jones P, Larson SM, J Control Release, 1/1/2011
• The effects of patient-provider communication on 3-month recovery from acute low back pain  
  Shaw WS, Pransky G, Roter DL, Winters T, Tveito TH, Larson SM, J Am Board Fam Med, 1/1/2011
• SNM CMIIT Hosts Prostate Cancer Summit  
  Larson SM, J Nucl Med, 1/1/2011
• Join now to see all

Books/Book Chapters

• Pathopysiology and Clinical Applications 
  Chapter: Nuclear Oncology 
  Page 3 - 19Strauss, HWS., Mariani, G., Volterrani, D., Larson, SMSpringer, New York, NY2012
• Liebel and Philips Textbook of Radiation Oncology 
  Chapter: Cancer of the Thyroid. Chapter 34 
  Page 726 - 736Swift, P., Larson, SM., Clark, O., Ruan, DElsevier Suanders, Philedelphia, PAEdition 3rd,2010
• A Practical Manual of Thyroid and Parathyroid Disease. 
  Chapter: The Role of Nuclear Medicine. Section 1 
  Grewal R, Larson SM, Carrasquillo JWiley Blackwell, United Kingdom2009
• Best Practice Research. Clinical Endocrinology & Metabolism. Volume 22 Number 6, Thyroid Nodules and Cancer. 
  Chapter: The value of position emission tomography (PET) in the management of patients with thyroid cancer. 
  Page 1047 - 1059Robbins RJ, Larson SM2008
• Nuclear medicine: Diagnostic Evaluation of Metastatic Disease. 
  Chapter: Contemporary Issues in Cancer Imaging Prostate Cancer. Chapter 11 
  Larson SM, Pandit-Taskar N2007
• Molecular Anatomic Imaging PET-CT and SPECT-CT Integrated Modality Imaging 
  Chapter: Thyroid Cancer Imaging with PET and SPECT. 
  Page 315 - 326Larson, Steven M., Grewal, Ravinder K., Tuttle, Michael MEditors: Gustav K. von Schulthess.Philadelphia, PAEdition 2nd,2007
• Molecular Anatomic Imaging PET-CT and SPECT-CT Integrated Modality Imaging 
  Chapter: PET and PET-CT in Radiation TreatmentdPlanning. 
  Page 501 - 516Larson, Steve M., Rosenzweig, Kenneth, Schoder, Heiko, Humm, JohnEditors: Gustav K. von Schulthess.LWW, Philadelphia, PAEdition 2nd,2007
• Nuclear Medicine 
  Chapter: The Future of Nuclear Medicine: Molecular Imaging and Radiotherapy. 
  Page 1556 - 1564Larson, Steven MEditors: Henkin, Robert E.Mosby, Philadelphia, PAEdition 2nd,2006
• Manual of Clinical Oncology 
  Chapter: Nuclear Medicine. 
  Divgi C, Larson SMEditors: Dennis A Casciato.Lippincott Williams and Wilkins, Philadelphia, PA2004
• Textbook of C Radiation Oncology 
  Chapter: Cancer of the Thyroid 
  Swift PS, Larson SM, Price DEditors: Leibel and Philips.Sauders, Philadelphia, PAEdition 2nd,2004
• Principles and Practice of the Biologic Therapy of Cancer 
  Chapter: Radioisotope Conjugates. 
  Larson SM, Divgi CR, Sgouros G, Cheung N-K, Scheinberg DAEditors: Rosenberg SA.Lippincott Inc., Philadelphia, PAEdition 3rd,2000
• Application of accelerators in research and industry; proceedings of the fifteenth international conference, part two. 
  Chapter: Low energy cyclotron production and separation of yttrium-86 for evaluation of monoclonal antibody pharmacokinetics and dosimetry. 
  Page 991 - 993Finn RD, McDevitt M, Ma D, Jurcic J, Scheinberg D, Larson SM, Shoner S, Link J, Krohn K, Schlyer DEditors: Duggan JL, Morgan IL.American Institute of Physics, Woodbury, NY1999
• Nuclear Medicine: Endocrinology 
  Chapter: Bone and parathyroid imaging. 
  Page 252 - 269Chestnut III CH, Larson SMEditors: BRothfeld.J.B. Lippincott1998
• Encylopedia of Cancer, Vol III 
  Chapter: Radiolabeled Antibodies: General Issues. 
  Page 1420 - 1431Larson SM, Sgouros G, Cheung N-KEditors: J.R. Bertino.Academic Press, CA1997
• Application of accelerators in research and industry; proceedings of the fourteenth international conference. 
  Chapter: Application of PET radionuclides for nuclear medicine targeted therapies. 
  Page 1345 - 1347Finn R, Macapinlac H, Humm J, Pentlow K, McDevitt M, Tjuvajev J, Blasberg R, Scheinberg D, Larson SM, Zweit JEditors: Duggan JL, Morgan IL.American Institute of Physics, Woodbury, NY1996
• Comprehensive Textbook of Thoracic Oncology. 
  Chapter: Imaging of thoracic neoplasms. 
  Page 112 - 168Heelan RT, Larson SMEditors: Aisner J, ArriagadaR, Green MR, Martini N, Perry MC.Williams & Wilkins, Baltimore, MD1996
• Clinical PET in Oncology. 
  Hustinx R, Paulus P, Rigo P, Yeung HW, Macapinlac HA, Larson SMGE Medical Systems, Europe, Paris, France1996
• Cancer: Principles and Practice of Oncology. 
  Chapter: Radionuclide Imaging. 
  Page 31 - 37Larson SMEditors: DeVita V, Hellman S, Rosenberg S.Lippincott-Raven, Philadelphia, PA1996
• Biologic Therapy of Cancer: Principles and Practice. 
  Chapter: Radioisotope Conjugates. 
  Page 534 - 552Larson SM, Sgouros G, Cheung N-K VEditors: DeVita VT Jr., Hellman S, Rosenberg SA.JP Lippincott, Philadelphia, PAEdition 2nd,1995
• Chemists' views of imaging centers. 
  Chapter: Radionuclides and their application in oncology research. 
  Page 277 - 284Finn RD, Divgi C, Goldsmith S, Larson SM, Macapinlac HA, Scott A, Yeh SDJEditors: Emran A.Plenum Press, New York, NY1995
• American college of nuclear physicans handbook on quality control in nuclear medicine 
  Chapter: Radiolabeled antibody imaging: applications and methodology. 
  Divgi CR, Sgouros G, Daghighian F, Larson SM1995
• Nuclear Medicine in Clinical Diagnosis and Treatment, Volume II 
  Chapter: Tumor diagnosis and therapy. "Thalium-201 Chloride: A tumor imaging agent". 
  Page 727 - 736Abdel-Dayem H, Larson SM, Macapinlac HA, Scott AMEditors: Murray IPC, Ell P.Churchill Livingstone Publishers, London1994
• Nuclear Medicine Annual 
  Chapter: Role of 201 Tl chloride and m Tc sestamibi in tumor imaging. 
  Page 181 - 234Abdel-Dayem99KHM, Scott AM, Macapinlac HA, El-Gazzar,AH, Larson SMEditors: Freeman LM..Raven Press, Ltd., New York, NY1994
• CANCER Principles & Practice of Oncology. 
  Chapter: Imaging techniques in cancer. 
  Page 507 - 531Castellino RA, DeLaPaz RL, Larson SMEditors: DeVita VT,Jr., Hellman S, Rosenberg SA.JB Lippincott, Philadelphia, PAEdition 4th,1993
• Frontiers in Nuclear Medicine, Diagnostic Uses of Radiolabeled Monoclonal Antibodies, Proceedings of Symposium 9/26-27/91 
  Chapter: Current status of radioimmunodetection of human tumors. 
  Page 1 - 14Larson SMEditors: M.K. Haseman.ACNP, Washington, DC1992
• Join now to see all

Lectures

• Harnessing the Power of the Atom for the Theranostics of Oncology: Targeted Radiotherapy and diagnosis 
  New Haven, CT - 1/23/2015
• Tumor Immunology-Multidisciplinary Science Driving Combination Therapy 
  Banff, Alberta, Canada - 1/8/2015
• Current Role of RAI Imaging and Therapy: Potential for I124 Imaging 
  Baltimore, MD - 1/4/2015
• Androgen Receptor Imaging Agents 
  Baltimore, MD - 1/4/2015
• Radio-Antibodies as Theranostics: The Role of PET Imaging 
  Washington, DC - 1/29/2013
• Molecular imaging and targeted therapy in oncology 
  Univeristy Hospital Cancer Center, Newark, NJ - 1/28/2013
• Breakout Session: Solid Tumors 
  Bethesda, MD - 1/18/2013
• State of the Art: Imaging in Prostate Cancer 
  Orlando, FL - 1/14/2013
• Targeted radionuclides as theranostics: the role of PET imaging 
  Berverly, MA - 1/4/2013
• Molecular Imaging for advanced practice oncology 
  Chicago, IL - 1/31/2012
• Prostate Cancer Imaging 
  Karolinska University Hospital, Stockholm, Sweden - 1/26/2012
• Supporting Radiology Research: Imaging Cores, Faculty Development 
  Chicago, IL - 1/25/2012
• Quantative PET imaging for the development of antibodies as drugs 
  National Harbor, MD - 1/19/2012
• Molecular Imaging and Therapy in Advanced Prostate and Thyroid Cancer 
  Miami, FL - 1/9/2012
• Programs Advancing Imaging Research: "CISC; NCI Imaging Steering Committee" 
  Pentagon City, VA - 1/4/2012
• Bone Scans for Prostate Cancer Metastasis 
  Palm Springs, CA - 1/20/2011
• Molecular Imaging Beyond FDG: A tool for In Vivo Study of Human Cancer Biology and Pharmacology 
  San Diego, CA - 1/7/2011
• Promising Novel Techniques in Molecular Imaging and Targeted Therapy of Cancer 
  San Antonio, TX - 1/2/2011
• PET/CT in Esophageal Cancer-Staging, Restaging and Evaluation of Treatment Response 
  Brazil - 1/28/2008
• Radionuclide Bone Scanning vs. 18Fluoro-2-Deoxyglucose-Positron 
  Washington, DC - 1/24/2008
• Radiotracers for Molecular Imaging and Drug Development 
  Tokyo, Japan - 1/20/2008
• Molecular Imaging in Drug Development and Chemistry I 
  Philadelphia, PA - 1/18/2008
• Oncologic Applications of PET Imaging 
  New York, NY - 1/17/2008
• The Role of PET-CT for the Medical Oncologist 
  UPENN - 1/15/2008
• Need for Quantitative SPECT & PET in Molecular Imaging 
  New Orleans, LA - 1/13/2008
• Join now to see all